Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer.

ABSTRACT: Extended small cell lung cancer (ED-SCLC) is a very aggressive disease, characterized by rapid growth and an early tendency to relapse. In contrast to non-small cell lung cancer, no therapeutic innovation has improved survival in patients with ED-SCLC over the past 20 years. Recently, immunotherapy has shown an important role in the management of these patients, emerging as the treatment of first choice in combination with chemotherapy and completely changing the therapeutic paradigm. However, patients' selection for this strategy is still challenging due to a lack of reliable predictive biomarkers. Conversely, the immunotherapy efficacy beyond the first line is pretty disappointing and innovative chemotherapies or target agents seem to be more promising in this setting. Some of them are a

SUBMITTER: Pierret T 

PROVIDER: S-EPMC7692868 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature